Home > Boards > US OTC > Delisted > Intellicell Biosciences, Inc. (fka SVFC)


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
ImOnABoat Member Profile
Member Level 
Followed By 533
Posts 9,639
Boards Moderated 2
Alias Born 05/02/09
160x600 placeholder
Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
By Josh Beckerman
Top Company News of the Day
Netflix Ends Down Nearly 22%, Worst Performer in the S&P 500 and Nasdaq 100 Today -- Data Talk
2-Year Treasury Yield Rises to 0.993% This Week -- Data Talk
10-Year Treasury Yield Falls to 1.747% This Week -- Data Talk
30-Year Treasury Yield Falls to 2.062% This Week -- Data Talk
Wheat Falls as U.S.-Russia Negotiations Continue - Daily Grain Highlights
Front Month Nymex Natural Gas Fell 6.17% This Week to Settle at $3.9990 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.97% This Week to Settle at $2.4424 -- Data Talk
GDP Seen +5.8% in 4Q -- Data Week Ahead
Canada's Omicron Infections May Have Peaked But Hospitalizations Rise, Health Officer Says
Coinbase Global Down Over 12%, on Track for Record Low Close and Record Percent Decrease -- Data Talk
EURO STOXX 50 Index Ends the Week 1.00% Lower at 4229.56 -- Data Talk
CAC 40 Index Ends the Week 1.04% Lower at 7068.59 -- Data Talk
STOXX Europe 50 Index Ends the Week 0.44% Lower at 3781.98 -- Data Talk
STOXX Europe 600 Index Ends the Week 1.40% Lower at 474.44 -- Data Talk
FTSE 100 Index Ends the Week 0.65% Lower at 7494.13 -- Data Talk
DAX Ends the Week 1.76% Lower at 15603.88 -- Data Talk
FTSE 100 Ends the Week Lower, Losing Year-to-Date Gains
Ecolab Down Nearly 6%, on Track for Largest Percent Decrease Since July 2020 -- Data Talk
Intuitive Surgical Down Nearly 7%, on Pace for Largest Percent Decrease Since April 2020 -- Data Talk
GM Expanding Production of Electric Motor Parts in NY State
Walt Disney Worst Performer in the DJIA So Far Today -- Data Talk
Glaxo Unit Valuation Boost Looks Less Likely as Unilever Walks -- Market Insight
ImOnABoat Member Level  Thursday, 01/30/14 06:08:11 PM
Re: None
Post # of 91005 

***Updated: 1/30/2014***

Table of Contents:

1) The Industry
2) The Company
3) The People
4) The Science
5) The Patents
6) The Due Diligence

1) The Industry

Regenerative Medicine (RM) is currently a $15 billion market and is expanding rapidly. In fact, many are calling this LARGELY UNTAPPED market "The Internet of Healthcare," and it is projected to reach $300 billion by year 2020 as patient advocacy groups demanding shift to RM proliferate worldwide (source: US Department of Health and Human Services). 1.2 million patients have been treated to date with RM products and therapies. Currently, 300 private and 50 public companies exist with $4.7 billion in total market capacity. $1.5 billion in worldwide research funding projected to $14 billion in 10 years.

2) The Company

Intellicell is a fully-reporting company currently trading on OTCQB.

The Company's Website


Intellicell is an emerging leader in regenerative medicine using highly potent stromal vascular fraction cells derived from vasculature of fat tissue via uniquely efficacious technology that is patented in the United States with multiple patents pending internationally. The company is intentioned to enter the large and rapidly growing market of medical conditions where cellular therapies are far more effective than traditional techniques alone.


SHARES OUTSTANDING:1,369,825,849 as of January 28, 2014 (latest filing)


3) The People


Dr. Steven Victor, founder and CEO of IntelliCell has been at the forefront of clinical product and process development for over 20 years. The patent pending process that Dr. Victor has developed for IntelliCell™ has been in research for over 4 years. In addition to developing clinical products that are used nationally and internationally in the medical aesthetics field, Dr. Victor is a practicing dermatologist in New York City. He has been a sought after national figure for teaching physicians new clinical techniques worldwide for over 20 years. Dr. Victor has also been featured in national and local media as a clinical subject matter expert in regenerative medicine, medical aesthetics, and dermatology.

Watch the CEO talk about Intellicell below:

Board of Directors

Mr. Michael Hershman

IntelliCell BioSciences Appoints Mr. Michael Hershman as Chairman of the Board of Directors

Mr. Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. President and CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial institutions to assist on matters relating to the consult of senior-level officials and/or the entities with which they do business.

More on Mr. Hershman can be found on the website of Fairfax Group by following this link.

Here is a video in which Michael Hershman is awarded Columbia Business School’s 2013 Botwinick Prize in Business Ethics.

I suppose having a renowned business ethics expert and a successful businessman with multiple governmental connections as your BOD Chairman is not a bad thing ;)

Mr. Myron Holubiak

Myron Holubiak is currently President of 1-800-Doctors, Inc. Mr. Holubiak is also Chairman of the Board of Directors of BioScrip, Inc., an infusion and home health company, and Lead Independent Director of Ventrus BioSciences, Inc. From 1998 through 2001, Mr. Holubiak was President of Roche Laboratories, Inc. and previously in his career, he co-founded and served as CEO to Emron, Inc, a strategic marketing firm serving the pharmaceutical industry, which was acquired by Dunn & Bradstreet and IMS Health in 1995. Mr. Holubiak also currently serves on the Board of Trustees for the Academy of Managed Care Foundation.

Mr. Leonard L. Mazur

Mr. Leonard L. Mazur Co-founded Triax Pharmaceuticals, LLC and serves as its Chief Operating Officer. Mr. Mazur also Co-Founded Akrimax Pharmaceuticals in 2007. Mr. Mazur began his pharmaceutical career with Cooper Laboratories in 1971, where he served as a Product Manager for ophthalmology, dermatology and other products. He was responsible for creating and growing the business that was sold to Pierre Fabre, a French dermatology company, in 2002. In 1995, he founded Genesis Pharmaceutical, Inc., and served as its Chairman, Chief Executive Officer from 1995 to 2005 and President.

Mr. Sam Khashman

IntelliCell Biosciences Announces the Addition of Mr. Sam Khashman to Board of Directors

During the past 20 years, Mr. Khashman has successfully directed the creation and launch of 14 products and 3 companies in the healthcare, financial, and manufacturing sector. He currently serves as the President and Chief Executive Officer of Technology Partners, Inc. DBA IMAGINE Software. Mr. Khashman founded the company and created the IMAGINE practice management system that is currently used in 48 States by more than 10,000 physicians. In addition to his involvement in numerous civic and charitable organizations, Mr. Khashman serves on the board of the National Chamber Foundation, the public policy think tank of the U.S. Chamber of Commerce in Washington D.C.

Medical Advisory Board

Dr. James Andrews

IntelliCell BioSciences Inc. Announces James R. Andrews, M.D. Has Joined Its Medical Advisory Board

Doctor James Andrews is one of the founding members of Andrews Sports Medicine and Orthopaedic Center in Birmingham, Alabama. He is also a founder of the American Sports Medicine Institute (ASMI) a non-profit institute dedicated to injury prevention, education and research in orthopaedics and sports medicine. This foundation is recognized as one of the world’s leaders in this field. Doctor Andrews is internationally known and recognized for his skills as an orthopaedic surgeon as well as his scientific and clinic research contributions in knee, shoulder and elbow injury prevention and treatment. In addition, he has made major presentations on every continent, and has authored numerous scientific articles and books.

Everything you ever wanted to know about Dr. Andrews and how prominent he is in the athletic community can be found following this link. Credit: Sibware

A list of athletic celebrities treated by Dr. Andrews as of 5 years ago can be found following this link.

Could some of his NEW celebrity patients have been treated with the help of Intellicell’s technology, but not yet publicized?

Dr. Joshua Hackel.

Another member of Andrews Institute on Intellicell’s board of medical advisors is Dr. Joshua Hackel. His profile information can be found here.

Dr. Sydney Coleman

You can read more about Dr. Coleman's extensive stem cell projects funded by the Department of Defense through the Office of the Assistant Secretary of Defense for Health Affairs in this post by lee13.

Note that these fantastic people are just part of the group currently working to move Intellicell’s technology forward. Complete corporate profile for the company can be found following this link. Just Google some of the names not mentioned in this post to see that Intellicell is associated with crème de la crème of medical and scientific communities.

4) The Science

According to this PR, an antibody flow cytometry study of IntelliCell's technology was performed by Millipore, a division of Merck (NYSE: MRK) and found that:

"IntelliCell's proprietary technology yield an average of 10 times (10X) the number of SVF cells containing adult adipose stem cells from less fat (only 2 oz) than that which the Company believes is used by any of its present competition utilizing enzymes in their process. The study also showed that IntelliCells™ contain all of the viable cells that are manufactured by competing technologies that use enzymatic digestion."

Click on this link to see the original figures from the Millipore studies of Intellicells. Credit: cazual

The following image presents cell culturing report using Intellicell’s technology:

Moreover, it is because no enzymes are necessary in Intellicell’s process that they are the only public commercial stem cell company in the United States to meet FDA Rule 361 exemption. Under the FDA’s Rule 361, IntelliCells is currently authorized to commercially sell its SVF stem cells in the U.S. The PR announcing the most recent FDA inspection of the company’s flagship lab can be found here. The copy of the FDA report can be obtained by following this link. Note that most of the observations cited in the report are minor and can be corrected easily. When the FDA spends four days in ANY lab, they WILL find something – it’s just the way the game goes.

Additionaly, the company previously announced that “it has received the results of its independent laboratory audit by Biologic Consultant Group and the audit showed that the new lab at 460 Park Avenue, New York, NY was cGTP compliant.”

Futhermore, as announced here, Intellicell “has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P's) such as the IntelliCell autologous stromal vascular fraction cellular product.”

Intellicell Biosciences wins key listing from the FDA

Finally, according to this news release, Intellicell “has been granted a Research Tissue Banking License by the New York State Department of Health.” Which will now allow the company to engage in “the development of autologous and allogenic stromal vascular fraction tissue for researchers around the world.”

A great summary of Intellicell’s technology as compared to current competitors can be found on page 19 of the company’s most recent investor presentation. The visual comparison is presented below:

A list of Intellicell’s current human clinical trials, as officially reported by the company in the latest investor presentation can be found in this post by lee13.

Here is an additional link to a prospective pilot study using Intellicell’s technology on the successful clinical application of SVFC on the gingival recession defects.

And an additional link to a planned study using Intellicell’s technology for Diabetic Foot Ulcers.

Finally, following is a collection links to official progress reports by the company in regards to successful use of technology for some of the most prominent conditions in today’s healthcare.

IntelliCell Biosciences' Cellular Therapy Treatment Yields Positive Results in Multiple Sclerosis Patients

IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella Tendinitis

IntelliCell Biosciences Stem Cells Used to Successfully Treat Bell's Palsy and Type I Diabetes Patient

Moreover, Dr. Babak Azizzadeh, one of the more prominent doctors in the nation, certainly a superstar in his field, acknowledges the Intellicell’s success.

Babak Azizzadeh, MD, FACS, Director of the Facial Paralysis Institute, comments on the recent treatment of a Bell’s palsy patient with stromal vascular fraction cells.

5) The Patents

IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology

You can find the U.S. patent overview here.

But not only is Intellicell’s technology fully patented in the United States, there are also multiple international patent applications that are pending. Links to European, Australian, Canadian, Thailand and Korean patents can be found in cazual’s post following this link.

It is clear that these patents when granted will open up a whole world of unique revenue-generating possibilities, especially in the countries and jurisdictions where stem cell laws and regulations are much more progressive than in the United States.

And the most important patent of them all, the European one, is one final step away from being granted! The news could come any day now! See the image below (courtesy of Sir Francelote)

6) The Due Diligence

In December 2013, Dr. Victor returned back from the business trip to a world-renowned hospital in Korea that is actively engaged in stem cell treatments of international celebrities. Related DD and picture confirmation of the trip can be found in this post.

Another impressive picture from the CEO's Korean trip can be seen here. (Source: Dr. Victor's Twitter Account)

More amazing pictures from the Korean trip can be found in this post by click5.

Here is a list of medical staff from CHAUM Global Stem Cell Clinical Trials Center.

Find the pictures of Intellicell's flagship clinic by following this link. Credit: Sir Francelote

Stervc’s comparison and contrast between SVFC and their main competitor CYTX can be seen here.

Stervc's post on SVFC & Bereskin & Parr LLP connection can be found by following this link.

Some notes on why Intellicell's process without enzymes is superior to that of CYTX, can be read in this post and also here.

You can read my thoughts on why Intellicell's debt is not all that bad by following this link.

The company's business plan is discussed here.

Forbes article discussing Intellicell's advantage.
“A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.”

Some calculation and comparison of cell yield from Intellicell and their competitors can be found in this post.

As shown here some of the insiders do believe in this company enough to trust it with couple hundred thousand dollars out of their own pockets.

Here is a link to a post by iHub member LJ Silver about a mystery investor who was willing to provide Intellicell with $500,000 of cold, hard cash.

Sir Francelote provides some quick DD in regards to where Intellicell stands against its competitors in this post.

lee13 shares some good thoughts on the likelihood of a buyout in this post.

Even if the FDA fails to support stem cell industry in the US – multiple international patents (See “The Patents”) will open up countless business possibilities abroad, where regulations in regards to human use of stem cells is much more progressive. And let’s not forget that Intellicell can still explore and capitalize upon less regulated US markets in cosmetics and veterinarian care. In fact, the company has already investigated veterinary market as per this PR.

Let’s not forget that the CEO is NOT getting paid until Intellicell is generating some significant revenues as explained by TheSkunk.

If you ever wondered about the reasons why Intellicell used to trade at $4 but is now a penny stock, you can read some thoughts on this matter that are posted right here.

You can read about Intellicell's relationship with ReGen Clinic by following this link.


Most Recent Investor Presentation (February 2013)

Most Recent (7.11.2013) Intellicell's CEO interview (Audio)

Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process (July 8, 2013)

The CEO’s Twitter Account

Best of luck!


This post is my personal opinion. I do not provide investment advice.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences